Week in Review

Week in Review: "Convening a Conversation” on Health Care Policy

06.21.13 | By

As our President and CEO John Castellani emphasized, “Healthy debate is the foundation of progress and advancement.” This is something we feel very strongly about, and the initiatives announced this week show our commitment to being part of the ongoing dialogue around health care.

One such initiative is our new “Conversations” forum. Conversations allows influential voices from throughout the health care field to compare notes and exchange ideas on a variety of health care issues. The biopharmaceutical industry is leading this dialogue because it is uniquely positioned to convene innovators, stakeholders, patients, elected officials and others with views to share about the state of health care in the United States. After all, together we are greater than the sum of our parts. While there may be differences of opinion on certain policy issues, there is a common purpose of delivering high quality care to patients.

Castellani also sat down with POLITICO to discuss our mission and highlighted how Conversations contributes to PhRMA’s core mission of bringing research, progress and hope to millions of patients. Compiling opinions of influential thought leaders will help us work toward finding answers to the big issues that will shape health care during the next generation, and continue to develop our reputation as a “trusted source” and “thought leader” for the health care industry.

Engaging in an ongoing dialogue about health will mean forming alliances with different organizations to emphasize the importance of key issues. To this end, we recently joined the National Association of Manufacturers (NAM) and the U.S. Chamber of Commerce as part of the newly formed Alliance for Fair Trade with India (AFTI). Members of this coalition will educate the public and policy makers about unfair trading practices in India and the ongoing issue of intellectual property theft. When other countries don’t play by internationally recognized rules, U.S. jobs and innovation suffer.

Castellani has made it clear that we, as an organization, want the reputation of being engaged on the big health policy questions of the day. We want you to be involved, too. Check back next week for more about Conversations, and leave comments below to let us know what you would like to hear more about. 


Hide Comments

More On PhRMA — powered by PhRMApedia


Cost in Context